Recursion Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€55.52M - Cost of goods sold
€57.61M - Gross profit
-€2.09M - SG&A expenses
€186.31M - R&D expenses
€371.50M - EBITDA
-€510.09M - D&A
€37.91M - EBIT
-€559.76M - Interest expenses
€1.41M - EBT
-€559.25M - Tax expenses
€13.78K - Net income
-€559.12M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€33.39M - Changes in working capital
€45.46M - Operating cash flow
-€330.00M - Capex
€7.06M - Other investing cash flow
-€12.39M - Net investing cash flow
€222.12M - Total cash dividends paid
€0.00 - Issuance of common stock
€24.12M - Debt repayment
-€3.78M - Other financing cash flow
€123.86M - Net financing cash flow
€142.40M - Foreign exchange effects
€9.49M - Net change in cash
€49.73M - Cash at end of period
€459.93M - Free cash flow
-€322.94M
Balance sheet
- Cash and cash equivalents
€455.08M - Cash and short-term investments
€455.08M - Total receivables
€18.61M - Inventory
€0.00 - Other current assets
€32.17M - Total current assets
€505.87M - Property, plant & equipment
€166.80M - Goodwill
€141.53M - Intangible assets
€294.06M - Long-term investments
€4.85M - Other non-current assets
€8.11M - Total non-current assets
€616.18M - Total assets
€1.12B - Accounts payable
€16.64M - Short-term debt
€27.76M - Other current liabilities
€72.83M - Total current liabilities
€141.32M - Long-term debt
€58.23M - Deferred tax liabilities
€20.49M - Other non-current liabilities
€1.35M - Total non-current liabilities
€188.84M - Total liabilities
€330.15M - Common stock
€3.45K - Retained earnings
-€1.56B - Other equity
€37.58M - Total equity
€791.89M - Total liabilities and shareholders' equity
€1.12B
Company information
- Market capitalization
€1.71B - Employees
800 - Enterprise Value
€1.77B
Company ratios
- Gross margin
-
-3.8% Much better than peer group: -601.4% - EBITDA margin
-
-918.8% Much better than peer group: -28,423.1% - EBIT margin
-
-1,008.2% Much better than peer group: -28,666.3% - EBT margin
-
-1,007.3% Much better than peer group: -27,768.7% - Net margin
-
-1,007.1% Much better than peer group: -27,584.5% - ROE
-
-70.6% Much better than peer group: -10,957.6% - ROA
-
-49.8% Much better than peer group: -631.3% - Asset turnover
-
4.9% Even with peer group: 8.3% - FCF margin
-
-607.1% Much better than peer group: -25,040.6% - FCF yield
-19.7% - Efficiency ratio
1,018.8% - Net sales per employee
-
€69.40K - Net income per employee
-
-€698.89K